Related Experiment Video
Updated: Aug 7, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer
Diana Lüftner1, Michael P Lux2, Tanja N Fehm3
1Immanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany.
Abstract:
Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.
Insights
Recent advancements in CDK4/6 inhibitors and antibody-drug conjugates show improved survival for HR+/HER2- breast cancer. Genomic studies are guiding future combination therapies and treatment sequencing.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Recent large-scale studies have focused on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates in cancer treatment.
- Published results from these studies are influencing current research and clinical practice.
Purpose of the Study:
- To summarize the latest developments in CDK4/6 inhibitors and antibody-drug conjugates.
- To contextualize new findings within the current landscape of breast cancer research.
- To highlight emerging treatment strategies based on recent data.
Main Methods:
- Review of recently published journal articles and conference presentations.
- Analysis of data from large-scale genomic studies.
- Synthesis of information on efficacy and resistance mechanisms.
Main Results:
- New data from major CDK4/6 inhibitor studies are now available.
- Genomic studies provide insights into treatment efficacy and resistance.
- Sacituzumab govitecan demonstrates improved overall survival in HR+/HER2- breast cancer patients as a second-line therapy.
Conclusions:
- The latest findings support further investigation into combination therapies and treatment sequencing.
- Sacituzumab govitecan represents a significant advancement for a specific breast cancer subtype.
- Continued research is crucial for optimizing cancer treatment strategies.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis